{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:04:49Z","timestamp":1762898689896},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.eururo.2011.06.001","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T21:26:25Z","timestamp":1308864385000},"page":"431-433","source":"Crossref","is-referenced-by-count":35,"title":["How Well Can You Actually Predict Which Non\u2013Muscle-Invasive Bladder Cancer Patients Will Progress?"],"prefix":"10.1016","volume":"60","author":[{"given":"Richard J.","family":"Sylvester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.06.001_bib0005","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.06.001_bib0010","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.06.001_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","article-title":"Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non\u2013muscle-invasive bladder cancer","volume":"58","author":"Van Rhijn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.06.001_bib0020","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1464-410X.2010.09850.x","article-title":"Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumors: validation study on the European Association of Urology guidelines","volume":"107","author":"Sakano","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.06.001_bib0025","doi-asserted-by":"crossref","unstructured":"Hernandez V, De La Pena E, Martin MD, Blazquez C, Diaz FJ, Llorente C. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol. In press. DOI:10.1007\/s00345-010-0635-2.","DOI":"10.1007\/s00345-010-0635-2"},{"key":"10.1016\/j.eururo.2011.06.001_bib0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.06.001_bib0035","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.06.001_bib0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.urolonc.2009.03.017","article-title":"Role of biomarkers to predict outcomes and response to therapy","volume":"28","author":"Lotan","year":"2010","journal-title":"Urol Oncol"},{"issue":"Suppl 218","key":"10.1016\/j.eururo.2011.06.001_bib0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/03008880802283847","article-title":"Combining a molecular profile with a clinical and pathological profile: biostatistical considerations","volume":"42","author":"Sylvester","year":"2008","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.06.001_bib0050","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","article-title":"Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors","volume":"28","author":"Lee","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811006130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811006130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T21:50:44Z","timestamp":1543701044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811006130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0302283811006130"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.06.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}